All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 01 May 2018, it was announced in a press release that the US Food and Drug Administration (FDA) approved the Novartis CAR-T therapy, tisagenlecleucel (Kymriah), as an intravenous suspension for its second indication for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and transformed follicular lymphoma (tFL). This therapy is targeted to patients who do not respond to second or later line therapy, including autologous stem cell transplantation. Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma (PCNSL).
This CAR-T therapy received its first FDA approval in August 2017 for the treatment of pediatric and young adult R/R acute lymphoblastic leukemia (ALL) patients who do not respond to second or later line treatment.
Stephen Schuster, Professor at Penn Medicine and Director of the Lymphoma Program at the Abramson Cancer Center commented that "with this approval, physicians now have a meaningful therapeutic option that can achieve and maintain a sustained response without stem cell transplant along with a consistent safety profile."
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox